Resources Contact Us Home
Browse by: INVENTOR PATENT HOLDER PATENT NUMBER DATE
 
 
Immunomedics, Inc. Patents
Assignee:
Immunomedics, Inc.
Address:
Morris Plains, NJ
No. of patents:
218
Patents:


1 2 3 4 5










Patent Number Title Of Patent Date Issued
RE37710 Radiometal-binding analogues of luteinizing hormone releasing hormone May 21, 2002
Peptide, derivatives of leutenizing hormone releasing hormone that are capable of binding radionuclides are provided. The peptide derivatives are readily labeled with isotopes of rhenium or technetium, while retaining their ability to tightly bind LHRH receptors. Methods for preparing th
8586050 Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy November 19, 2013
Described herein are compositions and methods of use of radionuclide-antibody conjugates (for RAIT) and drug-antibody conjugates (ADC). The combination of RAIT and ADC was more efficacious than either RAIT alone, ADC alone, or the sum of effects of RAIT and ADC. The unexpected synerg
8574854 Anti-mucin antibodies for early detection and treatment of pancreatic cancer November 5, 2013
Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human PAM4 antibodies. The antibodies show novel and useful diagnostic characteristics, such as binding with high specificity to panc
8574575 RS7 antibodies November 5, 2013
This invention relates to monovalent and multivalent, monospecific binding proteins and to multivalent, multispecific binding proteins. One embodiment of these binding proteins has one or more binding sites where each binding site binds with a target antigen or an epitope on a target
8569054 Mammalian cell lines for increasing longevity and protein yield from a cell culture October 29, 2013
Disclosed are compositions and methods for increasing the longevity of a cell culture and permitting the increased production of proteins, preferably recombinant proteins, such as antibodies, peptides, enzymes, growth factors, interleukins, interferons, hormones, and vaccines. Cells
8568729 Anthracycline-antibody conjugates for cancer therapy October 29, 2013
The invention relates to therapeutic conjugates with the ability to target various antigens. The conjugates contain a targeting antibody or antigen binding fragment thereof and an anthracycline chemotherapeutic drug. The targeting antibody and the chemotherapeutic drug are linked via
8287865 Class I anti-CEA antibodies and uses thereof October 16, 2012
The present invention provides compositions and methods of use of humanized, chimeric or human Class I anti-CEA antibodies or fragments thereof, preferably comprising the light chain variable region CDR sequences SASSRVSYIH (SEQ ID NO:1); GTSTLAS (SEQ ID NO:2); and QQWSYNPPT (SEQ ID
8287864 Structural variants of antibodies for improved therapeutic characteristics October 16, 2012
The present invention provides substituted humanized, chimeric or human anti-CD20 antibodies or antigen binding fragments thereof and bispecific antibodies or fusion proteins comprising the substituted antibodies or antigen binding fragments thereof. The antibodies, fusion proteins or
8268319 Immunoconjugates with an intracellularly-cleavable linkage September 18, 2012
The invention relates to therapeutic conjugates with improved ability to target various cancer cells containing a targeting moiety and a therapeutic moiety. The targeting and therapeutic moieties are linked via an acid cleavable linkage that increases therapeutic efficacy of the immu
8268317 Camptothecin-binding moiety conjugates September 18, 2012
The invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a camptothecin as a therapeutic moiety, and further relates to processes for making and using
8268312 Alpha-fetoprotein Immu31 antibodies and fusion proteins and methods of use thereof September 18, 2012
The present invention provides humanized, chimeric and human anti-alpha-fetoprotein antibodies, fusion proteins, and fragments thereof. The antibodies, fusion proteins, and fragments thereof, as well as combinations with other suitable antibodies, are useful for the treatment and dia
8216572 Antibody therapy July 10, 2012
The present invention provides a composition comprising naked humanized, chimeric, and human anti-CEA antibodies and a therapeutic agent, which is useful for treatment of CEA expressing cancers and other diseases, and methods of use in treatment using this composition.
8202509 Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules June 19, 2012
The present application discloses compositions and methods of synthesis and use of .sup.68Ga, .sup.18F or .sup.19F labeled molecules of use in PET or MRI imaging. Preferably, the .sup.18F or .sup.19F is conjugated to a targeting molecule by formation of a complex with a group IIIA metal
8192739 Fusion proteins containing recombinant cytotoxic RNAses June 5, 2012
Recombinant immunotoxins containing a cytotoxic RNAse fused to an antibody or antibody fragment may be produced in mammalian cell culture. Surprisingly, immunotoxins containing a cytotoxic RNAse fused to the N-terminus of one antibody variable domain can be prepared and retain the ab
8188239 Multivalent carriers of bi-specific antibodies May 29, 2012
Provided herein are targetable constructs that are multivalent carriers of bi-specific antibodies, i.e., each molecule of a targetable construct can serve as a carrier of two or more bi-specific antibodies. Also provided are targetable complexes formed by the association of a targeta
8168186 Therapeutic using a bispecific antibody May 1, 2012
Multivalent, multispecific molecules having at least one specificity for a pathogen and at least one specificity for the HLA class II invariant chain (Ii) are administered to induce clearance of the pathogen. In addition to pathogens, clearance of therapeutic or diagnostic agents, au
8163887 Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines April 24, 2012
Humoral and cellular immune responses against tumor cells and infectious agents are induced in a mammal using a vaccine comprising immunoconjugates that comprise antibodies and anti-idiotype antibodies that mimic an epitope of an antigen that is associated with a tumor or an infectio
8158573 Therapeutic and diagnostic conjugates for use with multispecific antibodies April 17, 2012
Disclosed are compounds that include two or more haptens conjugated by a spacer or a carrier. The haptens may include diethylenetriaminepentaacetate (DTPA), histimine-succinyl-glutamine (HSG), or combinations of DTPA and HSG. The compound also includes an effector molecule which may
8153433 Mammalian cell lines for increasing longevity and protein yield from a cell culture April 10, 2012
Disclosed are compositions and methods for increasing the longevity of a cell culture and permitting the increased production of proteins, preferably recombinant proteins, such as antibodies, peptides, enzymes, growth factors, interleukins, interferons, hamiones, and vaccines. Cells
8153101 Methods and compositions for F-18 labeling of proteins, peptides and other molecules April 10, 2012
The present application discloses compositions and methods of synthesis and use of F-18 labeled molecules of use, for example, in PET imaging techniques. In particular embodiments, the labeled molecules may be peptides or proteins, although other types of molecules including but not
8153100 Methods and compositions for F-18 labeling of proteins, peptides and other molecules April 10, 2012
The present application discloses compositions and methods of synthesis and use of .sup.18F or .sup.19F labeled molecules of use in PET or MRI imaging. The labeled molecules may be peptides or proteins, although other types of molecules may be labeled. Preferably, the .sup.18F or .su
8147831 Anti-CD19 antibodies April 3, 2012
The present invention provides humanized, chimeric and human anti-CD19 antibodies, anti-CD19 antibody fusion proteins, and fragments thereof that bind to a human B cell marker. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various
8147800 Methods and compositions for F-18 labeling of proteins, peptides and other molecules April 3, 2012
The present application discloses compositions and methods of synthesis and use of F-18 labeled molecules of use, for example, in PET imaging techniques. The labeled molecules may be peptides or proteins, although other types of molecules may be labeled by the described methods. Pref
8147799 Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules April 3, 2012
The present application discloses compositions and methods of synthesis and use of F-18 labeled molecules of use, for example, in PET imaging techniques. In particular embodiments, the labeled molecules may be peptides or proteins, although other types of molecules including but not
8119101 Anti-CD74 immunoconjugates and methods of use February 21, 2012
Disclosed are compositions that include anti-CD74 immunoconjugates and optionally a therapeutic and/or diagnostic agent. In preferred embodiments, the immunoconjugates comprise one or more anti-CD74 antibodies or antigen-binding fragments thereof, conjugated to a liposome or micelle.
8105596 Immunotherapy of B-cell malignancies using anti-CD22 antibodies January 31, 2012
B-cell malignancies, such as the B-cell subtype of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, are significant contributors to cancer mortality. The response of B-cell malignancies to various forms of treatment is mixed. Traditional methods of treating B-cell malignancies,
8097252 Methods and compositions for administering therapeutic and diagnostic agents January 17, 2012
Methods and compositions are described for targeting therapeutic and diagnostic molecules to particular types of cells using targeting antibodies or other targeting moeities.
8084583 RS7 antibodies December 27, 2011
This invention relates to monovalent and multivalent, monospecific binding proteins and to multivalent, multispecific binding proteins. One embodiment of these binding proteins has one or more binding sites where each binding site binds with a target antigen or an epitope on a target
8084029 Alpha-fetoprotein Immu31 antibodies and fusion proteins and methods of use thereof December 27, 2011
The present invention provides humanized, chimeric and human anti-alpha-fetoprotein antibodies, fusion proteins, and fragments thereof. The antibodies, fusion proteins, and fragments thereof, as well as combinations with other suitable antibodies, are useful for the treatment and dia
8080250 Immunoconjugates with an intracellularly-cleavable linkage December 20, 2011
The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjug
8076140 Mammalian cell lines for increasing longevity and protein yield from a cell culture December 13, 2011
Disclosed are compositions and methods for increasing the longevity of a cell culture and permitting the increased production of proteins, preferably recombinant proteins, such as antibodies, peptides, enzymes, growth factors, interleukins, interferons, hormones, and vaccines. Cells
8067006 Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting o November 29, 2011
The present invention concerns methods and compositions for delivery of therapeutic agents to target cells, tissues or organisms. In preferred embodiments, the therapeutic agents are delivered in the form of therapeutic-loaded polymers that may comprise many copies of one or more the
8062636 Antibody therapy November 22, 2011
The present invention provides a composition comprising naked humanized, chimeric, and human anti-CEA antibodies and a therapeutic agent, which is useful for treatment of CEA expressing cancers and other diseases, and methods of use in treatment using this composition.
8057793 Anti-CD20 antibodies and fusion proteins thereof and methods of use November 15, 2011
The present invention provides humanized, chimeric and human anti-CD20 antibodies and CD20 antibody fusion proteins that bind to a human B cell marker, referred to as CD20, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies and autoimmune
8038983 Fluorinated carbohydrate conjugates October 18, 2011
Disclosed are novel conjugates that include fluorinated carbohydrate molecules and methods for synthesizing the conjugates. The fluorinated carbohydrate molecule may include a radioisotope. The method of synthesizing the conjugate is useful for labeling selected molecules, and the co
8017736 Alpha-fetoprotein Immu31 antibodies and fusion proteins and methods of use thereof September 13, 2011
The present invention provides humanized, chimeric and human anti-alpha-fetoprotein antibodies, fusion proteins, and fragments thereof. The antibodies, fusion proteins, and fragments thereof, as well as combinations with other suitable antibodies, are useful for the treatment and dia
7999083 Immunoconjugates with an intracellularly-cleavable linkage August 16, 2011
The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjug
7993626 Methods and compositions for F-18 labeling of proteins, peptides and other molecules August 9, 2011
The present application discloses compositions and methods of synthesis and use of F-18 labeled molecules of use, for example, in PET imaging techniques. The labeled molecules may be peptides or proteins, although other types of molecules may be labeled by the described methods. Pref
7951921 Multivalent carriers of bi-specific antibodies May 31, 2011
Provided herein are targetable constructs that are multivalent carriers of bi-specific antibodies, i.e., each molecule of a targetable construct can serve as a carrier of two or more bi-specific antibodies. Also provided are targetable complexes formed by the association of a targeta
7951369 Chimeric, human and humanized anti-granulocyte antibodies and methods of use May 31, 2011
The present invention provides humanized, chimeric and human MN3 antibodies, fusion proteins, and fragments thereof. The antibodies, fusion proteins, and fragments thereof, as well as combinations with other suitable antibodies, are useful for the treatment and diagnosis of granulocy
7943343 Production and use of novel peptide-based agents for use with bi-specific antibodies May 17, 2011
The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that is reactive against a targeted tissue and at least one other arm that is reactive against a targetable conjugate. The targetable conjugate encompasses a hapten to which antibodie
7939073 Immunotherapy of B-cell malignancies using anti-CD22 antibodies May 10, 2011
B-cell malignancies, such as the B-cell subtype of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, are significant contributors to cancer mortality. The response of B-cell malignancies to various forms of treatment is mixed. Traditional methods of treating B-cell malignancies,
7932212 Inhibition of placenta growth factor (PlGF) mediated metastasis and/or angiogenesis April 26, 2011
The present invention concerns methods and compositions for inhibiting angiogenesis and/or tumor growth, survival and/or metastasis. In particular embodiments, the methods and compositions may concern ligands against placenta growth factor (PlGF), such as BP-1, BP-2, BP-3 or BP-4. So
7931903 Internalizing anti-CD74 antibodies and methods of use April 26, 2011
The present invention provides humanized, chimeric and human anti-CD74 antibodies, CD74 antibody fusion proteins, immunoconjugates, vaccines and bispecific that bind to CD74, the major histocompatibility complex (MHC) class-II invariant chain, Ii, which is useful for the treatment and
7931890 Targeted combination immunotherapy of cancer and infectious diseases April 26, 2011
The present invention is directed to methods for treating cancer wherein more than one therapeutic agent is used, with each of the therapeutic agents having different tumor-killing capabilities, and wherein the therapeutic agents are delivered to the tumor sites using combined target
7919273 Structural variants of antibodies for improved therapeutic characteristics April 5, 2011
The present invention provides substituted humanized, chimeric or human anti-CD20 antibodies or antigen binding fragments thereof and bispecific antibodies or fusion proteins comprising the substituted antibodies or antigen binding fragments thereof. The antibodies, fusion proteins or
7919090 Antibody therapy April 5, 2011
The present invention provides a composition comprising naked humanized, chimeric, and human anti-CEA antibodies and a therapeutic agent, which is useful for treatment of CEA expressing cancers and other diseases, and methods of use in treatment using this composition.
7919087 Internalizing anti-CD74 antibodies and methods of use April 5, 2011
The present invention provides humanized, chimeric and human anti-CD74 antibodies, CD74 antibody fusion proteins, immunoconjugates, vaccines and bispecific that bind to CD74, the major histocompatibility complex (MHC) class-II invariant chain, Ii, which is useful for the treatment and
7914787 Production and use of novel peptide-based agents with bispecific antibodies March 29, 2011
The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that specifically binds a targeted tissue and at least one other arm that specifically binds a targetable construct. The targetable construct comprises a carrier portion which compris
7910103 Immunotherapy of B-cell malignancies using anti-CD22 antibodies March 22, 2011
B-cell malignancies, such as the B-cell subtype of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, are significant contributors to cancer mortality. The response of B-cell malignancies to various forms of treatment is mixed. Traditional methods of treating B-cell malignancies,
1 2 3 4 5

 
 
  Recently Added Patents
Clothes hanger
Radiation detector array
High-accuracy centered fractional fourier transform matrix for optical imaging and other applications
Asynchronous line interface rate adaptation to the physical layer with synchronous lines at the connection layer
Horizontal aggregations in a relational database management system
Display screen or portion thereof with graphical user interface
Extensible framework for client-based active network measurement
  Randomly Featured Patents
Method and machine for automatically mounting and tightening clamps
Pulse actuated hydraulic pump
Antisense modulation of microtubule-associated protein 4 expression
Score line groove for container end members
Functional food additives
Internal combustion engine
Suitcase
Dialkylaminosulfur trifluorides as fluorinating agents
Limited use cameras and films
Media hold-down system having cross process chambering